PHOENIX group

PHOENIX group

PHOENIX group was founded in 1994 as a pharmaceutical wholesaler and has since grown into Europe’s most broadly distributed healthcare-commerce platform. The company supplies public pharmacies, doctors, and medical institutions while simultaneously operating a multi-brand pharmacy retail network. Unlike pure distributors, PHOENIX holds equity stakes in the retail endpoints it serves, making it a vertically integrated owner-operator. The firm deploys capital across pharmaceutical wholesale, pharmacy retail, and logistics infrastructure. Its wholesale banner brands — including Tamro, Nomeco, OCP, and UnitedDrug — move prescription and over-the-counter products across 26 countries, while retail chains BENU, Apotek 1, Help Net, Rowlands Pharmacy, and McCabes capture consumer demand in local markets. PHOENIX also runs pharmacy-cooperation programs such as NUMARK and SZIMPATIKA, effectively franchising procurement and brand standards to independent pharmacists. Geographic coverage stretches from the Nordics to the Iberian peninsula and into Eastern Europe, with confirmed operations in Germany, the UK, Poland, Belgium, the Netherlands, Portugal, Romania, Serbia, and Latvia. PHOENIX group does not publicly disclose total assets or deployment figures. Its scale, however, is defined by physical infrastructure rather than AUM: the firm moves pharmaceutical product through a proprietary logistics network that serves as the backbone for its retail brands and wholesale clients. Philanthropic or family-office structures are not disclosed; the company functions as an operating corporate investor. In February 2026, the group announced that Executive Board Members Steve Anderson and Stefan Herfeld would step down, with Marcus Sowada and Thomas Wallisch named as successors (per the firm, February 2026). That transition signals a consolidation of operational responsibility under a leaner leadership team. What structurally differentiates PHOENIX is that it acts as an end-to-end market maker in European pharmaceutical distribution — it owns both the supply-chain infrastructure and the retail shelves that product lands on. The company’s pharmacy cooperation programs layer a capital-light franchising model on top of its owned retail real estate, allowing it to extract procurement margin and brand fees from independent pharmacy owners without taking full operating risk. Governance rests with a management board that combines logistics, pharmaceutical, and retail expertise; the recent succession suggests a deliberate move to align leadership with the firm’s next phase of operational integration.